GLYC (GlycoMimetics) רווח למניה בארבעת הרבעונים האחרונים

The development of GlycoMimetics, Inc. (GLYC) is independent of economic cycles, relying exclusively on medical progress. However, the lack of profitability and uncertainty regarding test outcomes create high financial vulnerability. Business success is constrained by strict FDA regulations and laboratory research results. The current annual EPS TTM growth value demonstrates profit dynamics, where the latest mark is 38.80.

Analyzing the resilience of GlycoMimetics, Inc. (GLYC) requires evaluating profit dynamics through the lens of shareholder value. This indicator measures the percentage change in net income per share over a rolling year, revealing the efficiency of the business's capitalization. By examining the EPS growth rate over the last 12 months YoY, an investor determines the market consensus point between supply and demand. For a biopharmaceutical developer specializing in glycobiology, this metric reflects the commercial return on innovations in leukemia therapy.